+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06982521

Phase 3 Randomized Study Comparing RLY-2608 Plus Fulvestrant Versus Capivasertib Plus Fulvestrant for PIK3CA-Mutant HRHER2- Advanced or Metastatic Breast Cancer After CDK46 Inhibitor Treatment

Led by Relay Therapeutics, Inc. · Updated on 2026-10-05

540

Participants Needed

243

Research Sites

191 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of two drug combinations for treating patients with hormone receptor-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. This phase 3, open-label, global study compares RLY-2608 zovegalisib plus fulvestrant against capivasertib plus fulvestrant following disease recurrence or progression after prior treatment with a CDK46 inhibitor. The study focuses on patients whose cancer has advanced locally or metastasized and have specific genetic mutations influencing treatment response. Participants will receive one of two treatment combinations zovegalisib taken orally twice daily together with fulvestrant given by intramuscular injection on specified days in a 28-day cycle, or capivasertib taken orally twice daily on an intermittent weekly schedule combined with the same fulvestrant regimen. Treatment cycles repeat every 28 days. The study will monitor and compare these combinations over several months to assess outcomes. Throughout the study, participants will undergo regular assessments including imaging scans to measure cancer progression, blood tests to monitor drug levels, and questionnaires to evaluate quality of life. Researchers will track progression-free survival, overall survival, response rates, duration of response, clinical benefit, and safety profiles. The study duration may extend up to approximately 77 months, with ongoing monitoring of health status and adverse events to gather comprehensive data on treatment impact.

CONDITIONS

Brief Title

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Research Team

R

Relay Therapeutics, Inc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here